Full Refs for Educated Guess to Accepted Practice: the Use of Oral Anti-Diabetic Agents

Educated Guess to Accepted Practice: The Use of Oral Anti- Diabetic Agents in Pregnancy Oded Langer, MD, PhD

Please note: This is the complete reference list for the above article found on page 959 in the print journal. For your convenience, a few of these references have been listed in the article, too.

REFERENCES

1. Piacquadio K, Hollingsworth DR, Murphy H: Effects of in-utero exposure to oral hypoglycemic drugs. The Lancet 338:866-869, 1991

2. Kemball ML, McIvert C, Milner RDG, et al. Neonatal hypoglycemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970;45:696-701.

3. Langer, O., Conway, D.L., Berkus, M.D., et al. A Comparison Glyburide and Insulin in Women with Gestational Diabetes Mellitus. New England Journal of Medicine, Vol. 343(16):1134-38, 2000.

4. Reece EA, Homko C, Miodovnik M, et al. A consensus report of the diabetes in pregnancy study group of North America Conference. J Maternal-Fetal Neonatal Med. 2002;12:362–364

5. Metzger BE, Buchanan TA, Coustan DR, de Leivia A, et al. Summary and Recommendations of the Fifth International Workshop – Conference on Gestational Diabetes Mellitus. Diabetes Care. July 2007; 30, ProQuest Medical Library pg. S251.

6. Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol. 2003;102:857–868 and Greene MF. Oral hypoglycemic drugs for gestational diabetes [editorial]. N Engl J Med. 2000;343:1178–1179

7. Greene MF. Oral hypoglycemic drugs for gestational diabetes [editorial]. N Engl J Med. 2000;343:1178–1179

8. Koren G. The use of glyburide in gestational diabetes: an ideal example of “bench to bedside.” Pediatr Res. 2001;49:734 9. Saade G. Gestational diabetes mellitus: a pill or a shot? [ editorial] Obstet Gynecol. 2005;105:456–457

10. Durnwald C, Landon MB. Glyburide: The new alternative for treating gestational diabetes? [editorial] Am J Obstet Gynecol 2005; 193, 1-2.

11. Catalano PM, Tyzbit ED, Wolfe RR, et al: Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol 264:E60-67, 1997

12. Langer O. The diabetes in pregnancy dilemma. Leading change with proven solutions. University Press of America 2006

13. Pendergrass M, Fazioni E, DeFronzo RA: Non-insulin-dependent diabetes mellitus and gestational diabetes mellitus: same disease, another name? Diab Reviews 3:566-583, 1995

14. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995; 44:1249-58.

15. American Diabetes Association: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 23:S27-31, 2000 (suppl 2)

16. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999. 7:139-53

17. Kim C, Newton KM, Knopp RH: Gestational diabetes and the incidence of type 2 diabetes. Diabetes Care 25:1862-68, 2002

18. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes 51:2796-2803, 2002

19. DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984;7:72-80.

20. Rossetti L, Giaaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13:610-30

21. Simonson DC, Farrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes Care 1984;33:838-45 22. Zharikova O, Ravindran S, Nanovskaya T, et al. The kinetics for glyburide metabolism by human and baboon livers and placentas. Am J obstet Gynecol 2006; 195(6): S185 (Abs).

23. Yogev Y, Ben-Haroush A, Chen R, et al. Undiagnosed asymptomatic hypoglycemia: Diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol 2004; 104:88-93

24. Krentz AJ, Bailey CJ. Oral Antidiabetic Agents: Current role in type 2 diabetes mellitus. Drugs 2005; 65(3):385-411

25. Turner RC, Cull CA, Fright V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. J Am Med Assoc 1999; 281:2005-12

26. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ 2000; 321:252-3

27. Yki-Jarvinen H Thiazolidinedions. N Engl J Med 2004; 351:1106-18

28. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Revs 1998; 6:132-45

29. Cortez J, Tarsa M, Agent S, et al. Randomized controlled trial of acarbose vs. placebo in the treatment of gestational diabetes. Am J Obstet Gynecol 2006; 195(6):S149 (Abs).

30. Enders AC, Blakenship TN: Comparative placental structure. Adv Drug Del Rev 38:3-16, 1999

31. Benirschke K, Kaufmann P, Baergen R. Human Placenta. Springer, New York 2006

32. Elliot B, Langer O, Schenker S, et al: Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 165:807-812, 1991

33. Elliot B, Schenker S, Langer O, et al: Comparative placental transport of oral hypoglycemic agents. A model of human placental drug transfer. Am J Obstet Gynecol 171:653-660, 1994

34. Elliot B, Langer O, Schussling F. A model of human placental drug transfer. Am J Obstet Gynecol 1997;176:527-30 35. Koren G: Glyburide and fetal safety: transplacental pharmacokinetic considerations. Reprod Toxicol 15:225-229, 2001

36. Nanovskaya TN, Nekhayeva, Hankins G, et al. (2006). Effect of human serum albumin on transplacental transfer of glyburide. Biochemical Pharmacology 72; 632-9

37. Kraemer J, Klein J, Lubetsky A, et al. Perfusion studies of glyburide transfer across the human placenta: Implications for fetal safety. (2006). Am J Obstet Gynecol 195, 270-4.

38. Gedeon C, Behravan J, Koren G, et al. Transport of glyburide by placental ABD Transporters: Implications in fetal drug exposure. Placenta 2006. 27; 1096

39. Langer O. Oral hypoglycemic agents and the pregnant diabetic: “From bench to bedside.”Seminars in Perinat 2002; 26(3):215-24.

40. Langer O. Oral hypoglycemic agents in pregnancy: Their time has come. J Maternal-Fetal and Neonatal Med 2002; 12: 376-83

41. Langer O. Oral Anti-Hyperglycemic Agents for the Management of Gestational Diabetes Mellitus. Obstet Gynecol Clin N Am. 34 (2007) 255- 274.

42. Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, et al. Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol 2006; 195:1081-5

43. Kovo M, Haroutiunian S, Feldman N, et al. Determination of metformin transfer across the human placenta using dually perfused ex-vivo placental cotyledon model. [abstract] Am J Obstet Gynecol December 2005;193(6): S85

44. Hague WM, Davoren PM, McIntyre D, et al. Metformin crosses the placenta: a modulator for fetal insulin resistance? BMJ 2004; 327:880-1

45. Vavky E, Zahlsen K, Spigset O, et al. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005; 83:1575-8

46. Hale TW, Kristensen JH, Hacket LP, et al. Transfer of metformin into human milk. Diabetologia 2002; 45:1509-14

47. Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into human milk. Clin Pharmacol Therap 2003; 73: 71-7.) 48. Sevillano J, Lopez-Perez IC, Herrera E, et al. Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates. Biochem J 2005; 389, 913-8

49. Chan LYS, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005; 83(4):955-8

50. Holmes HJ, Casey BM, Bawdon RE. Placental transfer of rosiglitazone in the ex vivo human perfusion model. Am J Obstet Gynecol 2006; 195, 1715-9

51. Patrikeeva S, Hemauer S, Nanovskaya T, Hankins G, Mahmoud A. Transplacental transfer and distribution of rosiglitazone. Am J Obstet Gynecol 2006; 195(6); S128 (Abs.)

52. Notelowitz M. Sulfonylurea therapy in the treatment of the pregnant diabetic. S A Med J 1971; 45:226-9

53. Towner D, Kjos SL, Montoro MM, et al: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 18:1446-1451, 1995

54. Langer O, Conway D, Berkus M, et al. There is no association between hypoglycemic use and fetal anomalies. Am J Obstet Gynecol 1999; 180(1) (Abst): S38

55. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil and Steril 2006; 86(3):658- 63

56. Glueck et al (Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-5

57. Jakubwicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrin Metab 2002; 87:524-9

58. Moore L, Clokey D, Briery C, et al. Metformin use in gestational diabetes: efficacy and maternal and neonatal outcomes. Am J Obstet Gynecol 2006; 195(6); S142 (Abs.)

59. Langer, O. Conway, D.L.: Level of Glycemia and Perinatal Outcome in Pregestational Diabetes. Journal of Maternal-Fetal Medicine. Vol 9, (1):35-41; Aug 2001 60. Langer O. A Spectrum of Glucose Thresholds May Effectively Prevent Complications in The Pregnant Diabetic Patient. Seminars of Perinatology vol. 26; no. 3 (June) 2002: pp 196-205

61. Langer O, Rodriguez DA, Xenakis EMJ, et al: Intensified vs. conventional management of gestational diabetes. Am J Obstet Gynecol 170:1036- 1047, 1994

62. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycemic agents in 118 diabetic pregnancies. Diabetic Med 2000; 17:507-11

63. Lim JM, Tayob Y, O'Brien PM, et al. A comparison between the pregnancy outcome of women with gestation diabetes treated with glibenclamide and those treated with insulin. Med J Malaysia. 1997;52(4):377-81

64. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med. 2004; 15(1):51-5

65. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004; 190(5):1438-9

66. Chmait R, Dinise T, Moore T.: Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinat 2004;24:617-22

67. Gilson G, Murphy N. Comparison of oral glyburide with insulin for the management of gestational diabetes mellitus in Alaskan native women. Am J Obstet Gynecol 2002, 187;6, S152

68. Velazquez MD, Bolnick J, Cloakey D. The use of glyburide in the management of gestational diabetes. Obstet & Gynecol 2003; 101 (4) suppl. 88S

69. Kahn BF, Davies JK, Lynch AM, et al. Predictors of glyburide failure in the treatment of gestational diabetes. Obst & Gynecol 107(6); 2006; 1303-09

70. Jacobson GF, Ramos G, Ching J, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol (2005); 193, 118-24

71. Bertini AM, Silva JC, Taborda W, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med (2005); 33; 519 72. Rochon M, Rand L, Roth L, et al. Glyburide for the management of gestational diabetes: Risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol (2006); 195, 1090-4

73. Langer O, Most O, Monga S. Glyburide: Predictors of treatment failure in Gestational Diabetes. Am J Obstet Gynecol 2006; 195(6); S136 (Abs.) .

74. Langer, O, Yogev, Y, Xenakis, E , et al: Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol. 2005 Jan;192(1):134-9.

75. Langer O, Yogev Y, Xenakis E, et al. Overweight and obese in gestational diabetes: The impact on pregnancy outcome. Am J Obstet Gynecol (2005). 192, 1768-76

76. Langer O, Monga S, Most O. Obese gestational diabetic women: Comparison of insulin and glyburide therapies. Am J Obstet Gynecol 2006; 195(6); 136S (Abs.).

77. Goetzel L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22:403– 406.